As per Data Bridge Market Research Analysis the global demyelinating diseases therapeutics market size was valued at USD 1.05 billion in 2025and is expected to reach USD 2.33 billion by 2033, at a CAGR of 10.50% during the forecast period
The market growth is primarily driven by the rising prevalence of demyelinating disorders such as multiple sclerosis and related autoimmune neurological conditions, along with increasing awareness, earlier diagnosis, and expanding access to disease-modifying therapies in both developed and emerging healthcare systems
Furthermore, continuous advancements in immunomodulatory and biologic therapies, coupled with growing investment in neurological research and the development of targeted treatment approaches, are strengthening the therapeutic pipeline. These factors are accelerating adoption of advanced demyelinating disease treatments, thereby significantly supporting overall market expansion